7Baggers

Eliem Therapeutics, Inc
(NASDAQ:ELYM) 

ELYM stock logo

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The compan...

Founded: 2018
CEO: Bob Azelby  
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 
                       
      operating expenses:
    		                   
      research and development
    		13,738,000 9,073,000 6,575,000 17,327,000 5,952,000 6,087,000 1,046,000 1,091,000 3,127,000 2,876,000 3,688,000 5,720,000 4,927,000 4,258,000 8,740,000 8,111,000 6,591,000 5,704,000 5,478,000 
      acquired in-process research and development, related party
    		      51,659,000             
      general and administrative
    		5,558,000 5,819,000 4,102,000 5,691,000 4,952,000 5,492,000 3,667,000 1,914,000 1,995,000 2,125,000 3,026,000 17,718,000 4,627,000 4,490,000 4,932,000 4,872,000 3,824,000 3,394,000 2,914,000 
      total operating expenses
    		19,296,000 14,892,000 10,677,000 23,018,000 10,911,000 11,732,000 56,372,000 3,005,000 5,122,000 5,001,000 6,714,000 23,438,000 9,554,000 8,748,000 13,701,000 13,132,000 10,703,000 9,383,000 8,707,000 
      income from operations
    		-19,296,000 -14,892,000 -10,677,000 -23,018,000 -10,911,000 -11,732,000 -56,372,000 -3,005,000 -5,122,000 -5,001,000 -6,714,000 -23,438,000 -9,554,000 -8,748,000 -13,701,000 -13,132,000 -10,703,000 -9,383,000 -8,707,000 
      yoy
    		76.85% 26.93% -81.06% 665.99% 113.02% 134.59% 739.62% -87.18% -46.39% -42.83% -51.00% 78.48% -10.74% -6.77% 57.36%     
      qoq
    		29.57% 39.48% -53.61% 110.96% -7.00% -79.19% 1775.94% -41.33% 2.42% -25.51% -71.35% 145.32% 9.21% -36.15% 4.33% 22.69% 14.07% 7.76%  
      other income:
    		                   
      interest income
    		1,826,000 2,037,000 2,173,000 2,287,000    1,341,000 1,349,000 1,261,000 1,110,000 900,000        
      foreign currency gain
    		-61,250 -33,000   -26,000 52,000 -2,000 -33,000 132,000 -228,000 384,000 248,000     98,000 -252,000 -12,000 
      total other income
    		1,780,000 2,004,000 2,011,000 2,237,000 2,495,000 2,837,000 1,483,000 1,308,000 1,481,000 1,033,000 1,494,000 1,148,000 1,792,000 -934,000 -895,000 -72,000 158,000 -232,000 -12,000 
      net income
    		-17,516,000 -12,888,000 -8,666,000 -20,781,000 -8,416,000 -8,895,000 -54,889,000 -1,697,000 -3,641,000 -3,968,000 -5,220,000 -22,290,000 -7,762,000 -9,682,000 -14,596,000 -13,204,000 -10,545,000 -9,615,000  
      yoy
    		108.13% 44.89% -84.21% 1124.57% 131.15% 124.17% 951.51% -92.39% -53.09% -59.02% -64.24% 68.81% -26.39% 0.70%      
      qoq
    		35.91% 48.72% -58.30% 146.92% -5.39% -83.79% 3134.47% -53.39% -8.24% -23.98% -76.58% 187.17% -19.83% -33.67% 10.54% 25.22% 9.67%   
      net income per share
    		-0.25 -0.19 -0.13 -0.31 0.04 -0.13 -1.81 -0.06 -0.13 -0.15 -0.19 -0.84 -0.29 -0.37 -0.56 -0.5 1.25 -0.7 -3.11 
      weighted-average common shares outstanding, basic and diluted
    		67,812,145 68,003,248 67,585,121                 
      comprehensive loss:
    		                   
      other comprehensive income:
    		                   
      unrealized gain on marketable securities
    		-34 151 32                 
      comprehensive loss
    		-17,550 -12,737 -8,634 -20,518 -8,594 -8,694 -54,889 -1,695 -3,632 -3,944 -5,160 -22,027 -7,539 -9,659 -14,679 -13,602 -10,650 -9,633  
      foreign currency loss
    		  -162,000 -50,000         1,032,000 -1,317,000 -1,042,000 -157,000    
      weighted-average number of shares used to compute net loss per share, basic and diluted
    		   67,462,450 48,163,301    26,987,122           
      unrealized gain on investments, net of tax of 0
    		   263 -178 201  2 9 24 60 263 -114.5 23      
      research and development, related party
    		    7,000 153,000         29,000 149,000 288,000 285,000 315,000 
      other income
    		    1,402,750 2,785,000 1,485,000      153,750 383,000 147,000 85,000 60,000 20,000  
      weighted-average number of shares outstanding used to compute net loss per share, basic and diluted
    		     67,014,183 30,349,562 27,638,528  27,071,053 26,840,555 26,492,438        
      other comprehensive loss:
    		                   
      change in fair value of redeemable convertible preferred stock tranche liability
    		                   
      accretion of redeemable convertible preferred stock to redemption value and cumulative preferred stock dividends
    		                 -1,322,000 -2,141,000 
      net loss attributable to common stockholders
    		            -7,762,000 -9,682,000 -14,596,000 -13,204,000 -10,545,000 -10,937,000 -10,860,000 
      weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted
    		             26,336,029 26,296,560 26,238,950  15,585,611 3,488,017 
      unrealized loss on investments, net of tax of 0
    		              -83 -398 -105 -18  
      net loss and comprehensive loss
    		                  -8,719,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 
                         
        assets
      		                   
        current assets:
      		                   
        cash and cash equivalents
      		35,685,000 25,803,000 22,682,000 29,020,000 87,229,000 146,175,000 223,140,000 105,031,000 93,112,000 57,353,000 25,294,000 34,437,000 43,585,000 35,944,000 32,602,000 31,931,000  62,819,000  
        short-term marketable securities
      		65,395,000 61,098,000 62,021,000 69,042,000 63,690,000 47,176,000   13,686,000 50,080,000 77,339,000 74,935,000 79,981,000 86,675,000 90,349,000 92,010,000 89,558,000 83,199,000  
        prepaid expenses and other current assets
      		4,769,000 4,063,000 2,681,000 2,218,000 3,953,000 4,260,000 2,857,000 4,192,000 3,457,000 5,001,000 11,611,000 10,802,000 10,827,000 10,552,000 10,125,000 9,342,000 11,772,000 12,614,000 5,321,000 
        total current assets
      		105,849,000 90,964,000 87,384,000 100,280,000 154,872,000 197,611,000 225,997,000 109,223,000 110,255,000 112,434,000 114,244,000 120,174,000 134,393,000 133,171,000 133,076,000 133,283,000 148,252,000 158,632,000 104,803,000 
        long-term marketable securities
      		59,572,000 88,930,000 102,702,000 99,783,000 61,610,000 24,576,000        6,961,000 11,701,000 25,911,000 24,919,000 23,619,000  
        operating lease right-of-use assets
      		505,000 562,000 618,000 451,000 490,000 12,000 21,000 111,000 199,000 286,000 372,000 662,000 471,000 585,000 697,000 807,000    
        property and equipment
      		288,000 318,000 314,000                 
        other long-term assets
      		1,530,000 1,530,000 1,368,000 226,000 215,000    15,000 15,000 1,658,000 1,249,000 128,000 141,000 4,631,000 2,418,000 70,000   
        total assets
      		167,744,000 182,304,000 192,386,000 200,740,000 217,187,000 222,199,000 226,018,000 109,334,000 110,469,000 112,735,000 116,274,000 122,085,000 134,992,000 140,858,000 150,105,000 162,419,000 173,241,000 182,251,000 107,627,000 
        liabilities and stockholders’ equity
      		                   
        current liabilities:
      		                   
        accounts payable
      		2,269,000 477,000 946,000 777,000 705,000 291,000 509,000 85,000 66,000 736,000 878,000 864,000 750,000 1,494,000 1,061,000 847,000 1,404,000 2,579,000 1,955,000 
        accrued expenses and other current liabilities
      		4,459,000 4,244,000 5,037,000 6,104,000 4,069,000 3,045,000 2,950,000 2,640,000 2,433,000           
        operating lease liabilities
      		256,000 228,000 222,000 155,000 157,000 58,000 100,000 225,000 334,000 401,000 485,000 464,000 300,000 352,000 439,000     
        total current liabilities
      		6,984,000 4,949,000 6,205,000 7,036,000 4,931,000 3,423,000 3,741,000 2,950,000 2,833,000 2,901,000 3,618,000 4,915,000 6,097,000 6,280,000 7,614,000 6,896,000 6,031,000 5,590,000 5,713,000 
        operating lease liabilities, net of current portion
      		285,000 352,000 417,000 319,000 375,000    15,000 58,000 100,000 223,000 180,000 219,000 256,000 381,000    
        total liabilities
      		7,269,000 5,301,000 6,622,000 7,355,000 5,306,000 3,423,000 3,741,000 2,950,000 2,870,000 2,993,000 3,773,000 5,225,000 6,277,000 6,499,000 7,870,000 7,277,000 6,038,000 5,590,000 5,713,000 
        commitments and contingencies
      		                   
        stockholders’ equity:
      		                   
        common stock, 0.0001 par value...
      		5,000 7,000 7,000                 
        additional paid-in capital
      		449,762,000 448,738,000 444,762,000 443,749,000 441,727,000 440,028,000 434,835,000 264,057,000 263,577,000 262,088,000 260,903,000 260,102,000 249,930,000 248,035,000 246,252,000 244,480,000 242,939,000 241,747,000 4,610,000 
        accumulated other comprehensive income
      		435,000 469,000 318,000 286,000 23,000 201,000            -18,000  
        accumulated deficit
      		-289,727,000 -272,211,000 -259,323,000 -250,657,000 -229,876,000 -221,460,000 -212,565,000 -157,676,000 -155,979,000 -152,338,000 -148,370,000 -143,150,000 -120,860,000 -113,098,000 -103,416,000 -88,820,000 -75,616,000 -65,071,000 -55,456,000 
        total stockholders’ equity
      		160,475,000 177,003,000 185,764,000 193,385,000 211,881,000 218,776,000 222,277,000 106,384,000 107,599,000 109,742,000 112,501,000 116,860,000 128,715,000 134,359,000 142,235,000 155,142,000 167,203,000 176,661,000  
        total liabilities and stockholders’ equity
      		167,744,000 182,304,000 192,386,000 200,740,000 217,187,000 222,199,000 226,018,000 109,334,000 110,469,000 112,735,000 116,274,000 122,085,000 134,992,000 140,858,000 150,105,000 162,419,000    
        stockholders’ equity
      		                   
        common stock, 0.0001 par value per share...
      		   7,000 7,000 7,000 7,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 1,000 
        other long-term liabilities
      		        22,000 34,000 55,000 87,000     7,000   
        accrued expenses, related party
      		     29,000         21,000 109,000 39,000 32,000 127,000 
        accounts payable, related party
      		      101,000        21,000     
        accrued expenses and other current liabilities, related party
      		      81,000             
        accumulated other comprehensive loss
      		        -2,000 -11,000 -35,000 -95,000 -358,000 -581,000 -604,000 -521,000 -123,000   
        accrued expenses
      		         1,764,000 2,255,000 3,587,000 5,047,000 4,434,000 6,072,000 5,481,000 4,588,000 2,979,000 3,631,000 
        operating lease liabilities, current
      		               459,000    
        cash
      		                46,922,000  99,482,000 
        liabilities, redeemable convertible preferred stock, and stockholders’ deficit
      		                   
        redeemable convertible preferred stock
      		                   
        redeemable convertible preferred stock, 0.0001 par value per share...
      		                   
        total liabilities, redeemable convertible preferred stock and stockholders’ equity
      		                173,241,000   
        liabilities, redeemable convertible preferred stock, and stockholders’ equity
      		                   
        redeemable convertible preferred stock, 0.0001 par value...
      		                  152,759,000 
        total liabilities, redeemable convertible preferred stock, and stockholders’ equity
      		                 182,251,000  
        long-term assets
      		                  2,824,000 
        stockholders’ deficit:
      		                   
        total stockholders’ deficit
      		                  -50,845,000 
        total liabilities, redeemable convertible preferred stock, and stockholders’ deficit
      		                  107,627,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 
                         
          cash flows from operating activities:
        		                 
          net loss
        		-17,516,000 -12,888,000 -8,666,000 -20,781,000 -8,416,000 -8,895,000 -54,889,000 -1,697,000 -3,641,000 -3,968,000 -5,220,000 -22,290,000 -7,762,000 -9,682,000 -14,596,000 -13,204,000 -10,545,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                 
          stock-based compensation expense
        		1,043,000 3,976,000                
          non-cash operating lease expense
        		57,000 56,000 49,000 39,000 33,000 9,000 90,000 88,000 87,000 86,000 110,000 122,000 114,000 112,000 109,000 108,000  
          accretion of discounts on marketable securities
        		-511,000 -523,000                
          depreciation and amortization expense
        		30,000 29,000                
          in-process research and development, related party
        		    0 0            
          unrealized foreign currency transaction loss
        		-5,000 -1,000                
          changes in operating assets and liabilities:
        		                 
          prepaid expenses and other current assets
        		-706,000 -1,382,000                
          other long-term assets
        		0 -162,000                
          accounts payable
        		1,792,000 -393,000 93,000 72,000 414,000 -217,000 -1,180,000 20,000 -672,000 -142,000 14,000 114,000 -744,000 434,000 213,000 -556,000 -1,176,000 
          accounts payable and accrued liabilities, related party
        		              -67,000 70,000 8,000 
          accrued expenses and other current liabilities
        		220,000 -792,000                
          operating lease liabilities
        		-39,000 -59,000 -50,000 -59,000 -36,000 -42,000 -125,000 -124,000 -110,000 -125,000 -102,000 -107,000 -91,000 -125,000 -142,000 -89,000  
          long-term liabilities
        		    0 0 0 -22,000 -12,000 -21,000 -33,000 88,000      
          net cash from operating activities
        		-15,635,000 -12,139,000 -11,148,000 -15,434,000 -5,521,000 -7,555,000 -667,000 -1,819,000 -947,000 3,490,000 -7,965,000 -15,177,000 -8,449,000 -4,175,000 -13,966,000 -10,779,000 -7,884,000 
          capital expenditures
        		0 -109,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
          free cash flows
        		-15,635,000 -12,248,000 -11,148,000 -15,434,000 -5,521,000 -7,555,000 -667,000 -1,819,000 -947,000 3,490,000 -7,965,000 -15,177,000 -8,449,000 -4,175,000 -13,966,000 -10,779,000 -7,884,000 
          cash flows from investing activities:
        		                 
          purchases of property and equipment
        		0 -109,000                
          purchases of marketable securities
        		-4,996,000 -23,712,000                
          maturities of marketable securities
        		30,534,000 39,081,000                
          issuance of promissory loan in connection with asset acquisition
        		    0 0            
          cash paid in connection with asset acquisition, net of cash received
        		                 
          net cash from investing activities
        		25,538,000 15,260,000 4,786,000 -42,751,000 -53,409,000 -71,789,000 -9,645,000 13,751,000 36,748,000 28,037,000 -1,601,000 5,797,000 14,278,000 8,509,000 15,688,000 -4,035,000 -8,051,000 
          cash flows from financing activities:
        		                 
          proceeds from exercise of stock options
        		                 
          pre-funded warrant issuance costs
        		                 
          proceeds from issuance of common stock in private placement, net of issuance costs
        		    0 0            
          net cash from financing activities
        		    41,000 2,271,000 128,402,000 15,000 288,000 528,000 24,000 1,000     38,000 
          effect of exchange rate changes on cash and cash equivalents
        		     108,000 19,000 -28,000  4,000 399,000 231,000  -992,000 -1,051,000 -177,000  
          net change in cash and cash equivalents
        		9,882,000 3,121,000 -6,338,000 -58,209,000 -58,946,000 -76,965,000 118,109,000 11,919,000 35,759,000 32,059,000 -9,143,000 -9,148,000 7,641,000 3,342,000 671,000 -14,991,000 -15,897,000 
          cash and cash equivalents at beginning of period
        		0 0 0 87,229,000 0 0 0 93,112,000 0 0 0 43,585,000 0 0 0 46,922,000 0 
          cash and cash equivalents at end of period
        		9,882,000 3,121,000 -6,338,000 29,020,000 -58,946,000 -76,965,000 118,109,000 105,031,000 35,759,000 32,059,000 -9,143,000 34,437,000 7,641,000 3,342,000 671,000 31,931,000 -15,897,000 
          supplemental disclosure of noncash investing and financing activities:
        		                 
          issuance of common stock in exchange for in-process research and development
        		    0 0            
          settlement of promissory loan in connection with asset acquisition
        		    0 0            
          accrued liabilities, related party
        		                 
          supplemental disclosure of cash flow information:
        		                 
          operating lease liabilities arising from obtaining right-of-use assets
        		 0                
          purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities
        		                 
          stock-based compensation
        		   2,022,000 1,658,000 2,922,000 512,000 465,000 1,202,000 656,000 777,000 10,171,000 1,895,000 1,783,000 1,772,000 1,541,000 1,154,000 
          accretion of discounts and amortization of premiums on investments
        		   -669,000 -525,000 -169,000 0 -63,000 -346,000 -753,000 -741,000 -491,000      
          foreign currency gain from remeasurement
        		   24,000 57,000            0 
          prepaid expenses and other assets
        		   1,893,000 513,000 -996,000 2,209,000 216,000 1,544,000 6,610,000 -809,000 25,000 -274,000 -427,000 -784,000 2,430,000 843,000 
          long-term assets
        		   -10,000 -215,000 0 0 15,000 1,000 1,642,000 -409,000 -1,119,000 12,000 4,489,000 -2,213,000 -2,348,000 -70,000 
          accrued expenses and other liabilities
        		   2,035,000    -745,000          
          purchase of marketable securities
        		   -58,751,000 -60,408,000    -1,000 -2,463,000 -38,533,000 -17,452,000 -6,714,000 -46,742,000 -8,926,000 -25,581,000 -8,051,000 
          proceeds from maturities of marketable securities
        		   16,000,000 6,999,000 0 0 13,751,000 36,749,000 30,500,000 36,932,000 23,249,000 20,992,000 55,251,000 24,614,000 21,546,000  
          effect of exchange rate changes on cash
        		   -24,000              
          cash paid for leases included in operating cash outflows
        		   69,000 44,000 43,000 130,000 133,000 131,000 132,000 123,000 121,000 117,000 118,000 118,000 109,000  
          supplemental disclosure of non-cash investing and financing activities:
        		                 
          deferred transaction costs accrued but not yet paid
        		       952,000          
          right-of-use asset impairment
        		        0 0        
          cash paid in connection with asset acquisition, net of cash acquired
        		    0 0            
          right-of-use assets obtained in exchange for lease liabilities
        		        0 0 0 313,000 0 0 0 915,000  
          accrued liabilities
        		     95,000    -491,000 -1,333,000 -1,459,000 613,000 -1,678,000 591,000 899,000 1,608,000 
          proceeds from the exercise of stock options
        		     2,271,000 8,652,000 15,000  528,000 24,000 1,000      
          supplemental disclosure of cash operating activities:
        		                 
          foreign currency loss from remeasurement
        		      -19,000 28,000 330,000 -4,000 -399,000 -231,000 -1,812,000 992,000 1,051,000 177,000  
          change in fair value of redeemable convertible preferred stock tranche liability
        		                0 
          proceeds from initial public offering, net of issuance costs
        		                 
          proceeds from issuance of redeemable convertible preferred stock and related tranche rights, net of issuance costs
        		                 
          conversion of redeemable convertible preferred stock to common stock
        		                0 
          amortization of premiums and accretion of discounts on investments
        		             -70,000 100,000 193,000  
          proceeds from issuance of common stock sold in initial public offering, net issuance costs
        		                 
          proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
        		                 
          cash flow from investing activities:
        		                 
          cash flows from operating activities
        		                 
          investment amortization
        		                 
          in-process research and development expenses
        		                 
          assets acquired in asset acquisition including cash
        		                 
          cash from purchase of in-process research and development from a related party
        		                 
          proceeds from initial public offering, net issuance costs
        		                 
          redeemable convertible preferred stock accretion